ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025
Gigaxonin Potentiates Antiviral Innate Immune Responses by Targeting cGAS and TREX1.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Initiation of Tertiary Lymphoid Structures for Cancer Immunotherapy.Research (Washington, D.C.) · 2026Review
- Gigaxonin Potentiates Antiviral Innate Immune Responses by Targeting cGAS and TREX1.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Innate immunity is the first line of defense against viral infections. Cyclic GMP-AMP synthase (cGAS) senses abnormal cytosolic double-stranded DNA (dsDNA) and triggers the production of interferon and proinflammatory cytokines to eliminate viruses, whereas three-prime repair exonuclease 1 (TREX1) directly digests cytosolic dsDNA, thereby preventing aberrant activation of cGAS. The precise regulation of the antiviral response by cGAS and TREX1 remains incompletely understood. In this study, it is reported that gigaxonin potentiates antiviral innate immune responses by targeting both TREX1 and cGAS. Gigaxonin controls TREX1 turnover in the steady state by mediating its ubiquitination and proteasomal degradation. It also enhances the ubiquitination of cGAS and increases its enzymatic activity in response to infection with herpes simplex virus type 1 (HSV-1). Furthermore, it is found that the binding of cGAS to gigaxonin is induced by HSV-1 infection and that this interaction inhibits the TREX1-gigaxonin interaction. The findings highlight the dynamic role of gigaxonin in enhancing antiviral innate immune responses by targeting both TREX1 and cGAS, suggesting that targeting gigaxonin may constitute a novel therapeutic approach for combating infectious diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.